All In Biotech

Drug Trial Radar · NCT04593940

Immune Modulators for Treating COVID-19

Randomized Master Protocol for Immune Modulators for Treating COVID-19

Last checked: Nov 20, 2026Latest source record: Sep 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,971 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,971

Actual

Start

Oct 15, 2020

Primary completion

Jan 30, 2022

Study completion Mar 5, 2022

Sponsor

Lead sponsor
Daniel BenjaminAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Center for Advancing Translational Sciences (NCATS); Biomedical Advanced Research and Development Authority
First posted
Oct 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization. Each agent will be evaluated as add-on therapy to the standard of care (SoC) in use at the local clinics, including remdesivir (provided). The SoC may change during the course of the study based on other research findings. Comparisons of the agents among themselves is not a research objective. The study population corresponds to moderately and severely ill patients infected with the coronavirus disease 2019 (COVID-19) virus. Recruitment will target patients already hospitalized for treatment of COVID-19 infection as well as patients being treated for COVID-19 infection in Emergency Departments while waiting to be admitted to the hospital. Patients both in and out of the ICU are included in the study population.

Conditions

  • Covid19

Interventions

  • InfliximabDrug

    study drug or matching placebo

  • AbataceptDrug

    study drug or matching placebo

  • RemdesivirDrug

    Standard of Care

  • cenicriviroc (closed to enrollment as of 3-Sep-2021)Drug

    study drug or matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Had Recovered by Day 28Time frame: Days 1-28

Locations

91 sites in 5 countries. Site status is shown where the registry gives one.

  • Banner University Medical Center

    Phoenix, Arizona

  • University of Arkansas Medical Sciences

    Little Rock, Arkansas

  • Scripps Clinical Medical Group

    La Jolla, California

  • UCLA - Ronald Reagan Medical Center

    Los Angeles, California

  • Riverside University

    Moreno Valley, California

  • UC Irvine Medical Center

    Orange, California

  • Stanford University Medical Center

    Palo Alto, California

  • UCLA Medical Center- Santa Monica

    Santa Monica, California

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia

  • University of Florida-Jacksonville

    Jacksonville, Florida

  • University of Illinois at Chicago

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas

    Kansas City, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Tulane School of Medicine

    New Orleans, Louisiana

  • University Medical Center New Orleans

    New Orleans, Louisiana

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Anne Arundel Medical Center

    Annapolis, Maryland

  • Johns Hopkins Medical Center

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • U Mass Memorial Medical Center

    Worcester, Massachusetts

  • U Mass University Medical Center

    Worcester, Massachusetts

  • MidMichigan Medical Center- Gratiot

    Alma, Michigan

  • MidMichigan Medical Center - Midland

    Midland, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • University of Missouri Health Care

    Columbia, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Trinitas Hospital

    Elizabeth, New Jersey

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Rutgers New Jersey Medical School

    New Brunswick, New Jersey

  • NYU Brooklyn

    Brooklyn, New York

  • University at Buffalo

    Buffalo, New York

  • Flushing Hospital Medical Center

    Flushing, New York

  • Jamaica Hospital Medical Center

    Jamaica, New York

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.